Improving Potency, Selectivity, and Water Solubility of Adenosine A1Receptor Antagonists: Xanthines Modified at Position 3 and Related Pyrimido[1,2,3‐cd]purinediones
- 3 August 2006
- journal article
- research article
- Published by Wiley in ChemMedChem
- Vol. 1 (8) , 891-902
Abstract
The structure–activity relationships of xanthine derivatives related to the adenosine A1receptor antagonists 8‐cyclopentyl‐1,3‐dipropylxanthine (DPCPX) and 1,3‐dipropyl‐8‐(3‐noradamantyl)xanthine (KW3902) were investigated by focusing on variations of the 3‐substituent. Aromatic residues were well tolerated by the A1receptor in that position. A moderate effect of stereochemistry was found for the 3‐(1‐phenylethyl)‐substituted analogue of DPCPX (S>R) at A1and A3receptors, whereas the opposite stereoselectivity was observed at the A2receptor subtypes. A 3‐hydroxypropyl substituent was found to be optimal for high A1affinity and selectivity. The most potent compound of the present series was 1‐butyl‐3‐(3‐hydroxypropyl)‐8‐(3‐noradamantyl)xanthine (10 c), which exhibits aKivalue of 0.124 nMat rat, and 0.7 nMat human adenosine A1receptors, combined with high selectivity (≫200‐fold) versus the other receptor subtypes. The similarly potent 8‐cyclopentyl‐3‐(3‐hydroxypropyl)‐1‐propylxanthine was converted into a water‐soluble phosphate prodrug, which may become a useful pharmacological tool for in vivo studies. 8‐Alkyl‐2‐(3‐noradamantyl)pyrimido[1,2,3‐cd]purine‐8,10‐diones, which can be envisaged as xanthine analogues with a fixed 3‐propyl substituent, were identified as a new class of potent, selective adenosine A1receptor antagonists. For example, compound14(8‐butyl‐substituted) exhibits aKivalue of 13.8 nMat human A1receptors. A selection of the most potent compounds was investigated in [35S]GTPγS binding assays and showed inverse agonistic activity. Their efficacy was generally lower than that of the full inverse agonist DPCPX, and depended on subtle structural changes. Some of the new compounds belong to the most potent and selective A1antagonists described to date.Keywords
This publication has 39 references indexed in Scilit:
- Synthesis and pharmacology of pyrido[2,3-d]pyrimidinediones bearing polar substituents as adenosine receptor antagonistsBioorganic & Medicinal Chemistry, 2006
- Multigram-Scale Syntheses, Stability, and Photoreactions of A2A Adenosine Receptor Antagonists with 8-Styrylxanthine Structure: Potential Drugs for Parkinson's DiseaseThe Journal of Organic Chemistry, 2004
- Antinociceptive Effects of Novel A2B Adenosine Receptor AntagonistsThe Journal of Pharmacology and Experimental Therapeutics, 2004
- Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in ratsSynapse, 2003
- Catalepsy induced by a blockade of dopamine D1 or D2 receptors was reversed by a concomitant blockade of adenosine A2A receptors in the caudate‐putamen of ratsEuropean Journal of Neuroscience, 2001
- Effect of γ-butyrobetaine on fatty liver in juvenile visceral steatosis miceJournal of Pharmacy and Pharmacology, 2001
- Electrophysiological and behavioural evidence for an antagonistic modulatory role of adenosine A2A receptors in dopamine D2 receptor regulation in the rat dopamine‐denervated striatumEuropean Journal of Neuroscience, 2000
- A Novel Ring Closure Reaction for the Preparation of 6-Aminouracils with an a-Branched 1-SubstituentHETEROCYCLES, 2000
- A1-Adenosine receptor antagonistsExpert Opinion on Therapeutic Patents, 1997
- Der synthetische Aufbau der Harnsäure, des Xanthins, Theobromins, Theophyllins und Caffeïns aus der CyanessigsäureEuropean Journal of Inorganic Chemistry, 1900